Advances in Cancer Therapy: Targeted Therapies

伊马替尼 主旨 髓系白血病 酪氨酸激酶 癌症研究 甲磺酸伊马替尼 癌症 酪氨酸激酶抑制剂 达沙替尼 靶向治疗 阿布勒 医学 受体酪氨酸激酶 间质细胞 内科学 受体
作者
Dieter Marmé
出处
期刊:Oncology Research and Treatment [Karger Publishers]
卷期号:39 (12): 758-759 被引量:3
标识
DOI:10.1159/000453340
摘要

As we learned to understand many of the mechanisms which drive cancer development and progression, a paradigmatic change for new treatment options occurred. Instead of focusing mostly on unspecific cytotoxic therapeutics, new substances directed against cancer-driving molecules made their way to the clinic. The idea behind this concept of ‘targeted cancer therapies' is quite simple: if we are able to bring cancer-driving molecules under control, we might be able to stop cancer development and progression. An outstanding example confirming this hypothesis is the successful treatment of chronic myeloid leukemia (CML) with imatinib. This treatment works so perfectly because the underlying genetic alteration of CML is a chromosomal translocation that leads to a constitutive activation of the BCL-Abl tyrosine kinase - imatinib inhibits its activity.Interestingly, after the successful use of imatinib against CML, it was found that the same compound could also be applied to treat gastrointestinal stromal tumors (GIST). Here again, the explanation is rather simple: imatinib not only inhibits the BCL-Abl-tyrosine kinase (one of about 500 protein kinases coded in the human genome), but also the c-KIT tyrosine kinase, which is mutated and activated in GIST. Furthermore in about 5-7% of GIST patients, the platelet-derived growth factor receptor alpha (PDGFRA) is mutated and activated. Its activity is also inhibited by imatinib. This explains to some degree the successful use of imatinib in the treatment of GIST.What does the imatinib story tell us? (i) ‘Targeted therapy' does work effectively (CML); (ii) a targeting compound does not necessarily have to be extremely specific. In the case of GIST, imatinib modulates the activity of 2 tumor-driving mutated protein kinases: BCL-Abl tyrosine kinase and PDGFRA tyrosine kinase. (iii) Activated protein kinases are often involved in tumor development and thus are potential targets for treatment.However, most tumors have a much more complex etiology than CML. Over time, sometimes over decades, they progress by accumulating many mutations, occurring in so-called oncogenes and/or tumor suppressor genes. This process results in progression of the disease and formation of metastases. This process (the types of mutations and their temporal occurrence) differs from tumor type to tumor type. Furthermore, within a given tumor entity, this process also differs from patient to patient. Thus, at present we are faced with quite a number of problems, which have to be solved in order to proceed with the development of ‘targeted therapies': - Identification of the molecular identities of tumor-driving mechanisms and their validation as ‘therapeutic targets'. In this area considerable progress has been made over the last years. - Diagnostic verification of the presence of therapeutic targets in the tumor of each individual patient. This gives us the necessary information as a prerequisite for ‘personalized cancer therapy'. Molecular pathology has successfully developed novel technologies, i.e. molecular and histological methods, such as next-generation sequencing or semi-quantitative immuno-histochemistry. A large effort has to be made to integrate these technologies into clinical studies and thus eventually to facilitate more refined guidelines, combining validated diagnostics with precision therapy in clinical practice. - Development of more compounds suited for targeted therapy. A large number of molecules and antibodies is already available. Many of them have been investigated in clinical studies and some of these have already found their way to the clinic. The knowledge of the individual transforming entities will help to stratify patients into subgroups suited for specific targeted treatments. This has already been shown to be a successful strategy. However, this approach might require large amounts of tumor tissue (and does not necessarily solve the problem of tumor heterogeneity). Thus alternative sources of tumor samples, such as blood (i.e. liquid biopsies), have to be explored to gain access to the complete signature of an individual tumor. First successful examples encourage us to proceed in this direction.These activities are ongoing. Together with the availability of more and quantitated target-specific diagnostic assays, targeted therapies will become increasingly successful in treating cancer. As in general tumors are driven by more than one oncogenic process, the combination of two or even more targeted compounds could increase their curative potential. So far, many of these novel treatment options are applied in combination with traditional cytotoxic substances. In this issue of Oncology Research and Treatment experts in the field summarize the achievements reached so far in selected tumor entities. They also address the deficits as they show up at present and give an outlook on the urgent needs in order to accomplish successful targetined therapy. Lung cancer is a prominent example where substantial progress has been made. Michels and Wolf [1] in particular address resistance problems and also the blood/brain barrier as a major hurdle to treat brain metastases. The therapy of chronic lymphocytic leukemia (CLL) can be improved in certain cases by combining different agents addressing different targets [2]. Head and neck cancer requires substantially more clinical studies investigating new compounds addressing the targets that have been shown to be involved in this disease [3]. To proceed with targeted therapy of esophagogastric cancer, we need much better diagnostics and more information on markers. This should considerably improve the evaluation of clinical investigations [4]. Metastatic colorectal cancer (mCRC) is treated basically by targeting an oncogenic molecule at the surface of the cancer cell on the one hand and tumor angiogenesis as a target coming from the cellular environment on the other [5]. As targeted therapies require substantial support from molecular pathology, Manfred Dietel [6] describes the current situation in this field and addresses the problems and the future developments.In summary, personalized targeted therapies are at present the most encouraging treatment strategies to advance in the battle against cancer. The first steps in this direction have been successful. However, there is still a long way to go. The Author declares no conflicts of interest.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
CodeCraft应助ouyggg采纳,获得10
1秒前
1秒前
隆咚锵发布了新的文献求助10
1秒前
李杍木发布了新的文献求助10
1秒前
2秒前
3秒前
DNase发布了新的文献求助10
3秒前
搜集达人应助唐唐采纳,获得10
3秒前
elysia发布了新的文献求助10
4秒前
Ava应助JINNA采纳,获得10
4秒前
了阿郎完成签到,获得积分10
4秒前
yy关注了科研通微信公众号
4秒前
李健应助yes采纳,获得10
5秒前
6秒前
6秒前
我是老大应助山丘采纳,获得10
6秒前
QUA应助Aten采纳,获得10
6秒前
7秒前
火星上香菇完成签到,获得积分20
7秒前
7秒前
笨小孩发布了新的文献求助10
8秒前
科目三应助小龚热心肠采纳,获得10
8秒前
活泼的机器猫完成签到,获得积分10
8秒前
9秒前
合适夏天完成签到,获得积分10
9秒前
鸽子的迷信完成签到,获得积分10
9秒前
10秒前
10秒前
jeanshe619完成签到,获得积分20
12秒前
李慧颖完成签到 ,获得积分20
12秒前
12秒前
花粉过敏完成签到,获得积分10
13秒前
13秒前
852应助乌龟娟采纳,获得10
13秒前
田様应助ly采纳,获得10
14秒前
14秒前
ouyggg发布了新的文献求助10
14秒前
杜四十929完成签到,获得积分10
14秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Picture Books with Same-sex Parented Families: Unintentional Censorship 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3970572
求助须知:如何正确求助?哪些是违规求助? 3515219
关于积分的说明 11177438
捐赠科研通 3250374
什么是DOI,文献DOI怎么找? 1795265
邀请新用户注册赠送积分活动 875750
科研通“疑难数据库(出版商)”最低求助积分说明 805054